Free Cardiology CME
1 - 6 of 6 results
- FREE
ScientiaCME Cardiology/Pulmonology
Target Audience: Physicians specializing in Cardiology, Chest Medicine, Family Medicine, Internal Medicine.
See full details chevron_right- Cost: Free
- Credit hours: 2
- CME credits awarded by: ScientiaCME
- Format: On-Demand Online
- Expiration of CME credit: Two years after release
- FREE
Advances in the management of Fabry disease
Fabry disease is characterized by a deficiency of the glycoside hydrolase enzyme alpha galactosidase A, resulting in the accumulation of the glycolipid globotriaosylceramide throughout the body, particularly prominently in the blood vessels. A defect in the enzyme alpha galactosidase A results in glycosphingolipid accumulation, ultimately leading to multi-organ dysfunction and the patient’s premature death. Early symptoms, which occur during childhood, involve pain and may include Raynaud phenomenon, paresthesias, and arthralgia in the extremities and proximal limbs, as well as impaired gastrointestinal emptying, resulting in abdominal pain, diarrhea, early satiety, postprandial bloating, nausea, and vomiting. In adulthood, the disease’s impact spreads beyond and begins to affect the cardiac and renal systems.
Target Audience:
The following healthcare professionals: cardiologists, nephrologists, pediatricians, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists; and any other healthcare professionals with an interest in or who may clinically encounter patients with Fabry disease.
By the end of the session the participant will be able to:
- Describe the pathophysiology of Fabry disease diagnosis and treatment.
- Describe the challenges associated with diagnosis of Fabry disease.
- List present and emerging treatment options for Fabry disease and apply them to patient cases using evidence-based medicine.
- Describe the benefits and any applicable risks of therapeutic approaches to Fabry disease and take them into account when formulating a treatment plan for patients.
- Cost: Free
- Credit hours: .75
- CME credits awarded by: ScientiaCME
- Format: On-Demand Online
- Material last updated: 08/13/2020
- Expiration of CME credit: 08/13/2022
- FREE
Reducing vascular events and disease progression in type 2 diabetes (T2DM) and optimizing delivery of care
Activity Description / Statement of Need:
In this online, self-learning activity:
Cardiovascular (CV) disease (CVD) is the leading cause of mortality and morbidity in adults worldwide, accounting for around one-third of mortality in the United States. High blood pressure, diabetes, and obesity are health conditions that can increase the risk of heart disease, and over half of American adults have at least one major risk factor for adverse cardiovascular events. In particular, T2DM is a risk factor, with CV events implicated in the mortality of two-thirds of patients with T2DM. About one and a half million new cases of diabetes mellitus are diagnosed in in the United States each year, and the incidence of T2DM is increasing owing in part to Western-style diets, sedentary lifestyle, and changing demographics, and the disease is the largest contributor to a number of vascular outcomes, including end-stage chronic kidney disease (CKD) and blindness in individuals under age 75. CKD is itself a major CVD risk factor and affects millions, yet the literature shows that patients with CKD are underserved with respect to CV risk reduction efforts.
This activity has been proposed to enhance the knowledge, competence, and performance of several members of HCPs in mitigating heart and kidney disease risk in patients with T2DM while addressing barriers to optimal care.
Target Audience:
The following HCPs: Endocrinologists, nephrologists, cardiologists, and primary care physicians; certified diabetes educators, physician assistants, nurse practitioners, nurses, and pharmacists who practice in diabetes and endocrinology; and any other HCPs with an interest in or who clinically encounter patients with diabetes.
See full details chevron_right- Cost: Free
- Credit hours: 1.5
- CME credits awarded by: ScientiaCME
- Format: On-Demand Online
- Material last updated: 12/16/2021
- Expiration of CME credit: 12/16/2023
- FREE
Transthyretin amyloidosis (ATTR): Prompt diagnosis contemporary management strategies and their impact on patient outcomes
Activity Description / Statement of Need:
In this online, self-learning activity:
Transthyretin amyloidosis (ATTR) is a progressive, multisystem, life-threatening disorder characterized by the extracellular deposition of misfolded, insoluble amyloid fibrils. The role of the TTR protein is to transport thyroxine and retinol-binding proteins, and it is vital for cognition, nerve regeneration, and axonal growth. TTR itself is innately amyloidogenic even without the presence of genetic mutations, which may account for wild-type ATTR (wtATTR), while a hereditary form of ATTR (hATTR) may be passed to offspring through autosomal dominant inheritance. Left untreated, the average life expectancy of ATTR is 3 to 15 years from symptom onset.
This accredited educational activity would identify the critical components of the management process and offer solutions to close gaps in diagnosis and care, with the ultimate goals being the improvement of ATTR management, treatment adherence when applicable, and health and cost outcomes.
Target Audience:
The following HCPs: neurologists, cardiologists, and hematologists; physician assistants, nurse practitioners, and pharmacists in the aforementioned areas of specialty; and any other HCPs with an interest in or who may clinically encounter patients with ATTR.
See full details chevron_right- Cost: Free
- Credit hours: 1
- CME credits awarded by: ScientiaCME
- Format: On-Demand Online
- Material last updated: 12/29/2021
- Expiration of CME credit: 12/29/2023
- FREE
Hereditary transthyretin amyloidosis (ATTR) treatment strategies: best practices and emerging therapies
Activity Description / Statement of Need:
In this online, self-learning activity:
Transthyretin amyloidosis (ATTR) is a progressive, multisystem, life-threatening disorder characterized by the extracellular deposition of misfolded, insoluble amyloid fibrils. As TTR is a protein present in human serum, and its role is to transport thyroxine and retinol-binding proteins, it is vital for behavior, cognition, nerve regeneration, and axonal growth. TTR itself is innately amyloidogenic even without the presence of genetic mutations. The familial variant of the disease (hATTR) is ATTR that is passed to offspring through autosomal dominant inheritance, whereas the wild type variant (wtATTR) refers to ATTR that occurs independently of genetic mutations. hATTR may present as late as mid-adulthood, but its symptoms usually start between the ages of 2 and 10 years. Left untreated, the average life expectancy of ATTR is 3 to 15 years from symptom onset.
Target Audience:
The following HCPs: neurologists, cardiologists, and hematologists; physician assistants, nurse practitioners, nurses, and pharmacists in the aforementioned areas of specialty; and any other HCPs with an interest in or who may clinically encounter patients with ATTR.
See full details chevron_right- Cost: Free
- Credit hours: 1
- CME credits awarded by: ScientiaCME
- Format: On-Demand Online
- Material last updated: 07/02/2021
- Expiration of CME credit: 07/01/2023
- FREE
Present and novel approaches to treating heart failure with reduced ejection fraction (HFrEF): Where to start and next-line strategies
Activity Description / Statement of Need:
In this online, self-learning activity:
Heart failure (HF) is a clinical syndrome arising from diminished ventricular filling or ejection of blood. HF with reduced ejection fraction (HFrEF) is characterized by abnormality in the systolic function and a left ventricular ejection fraction (LVEF) of <40%. The prevalence of HF is about 40 million people globally and approximately 6.5 million in the U.S., and as the global population continues to age, the prevalence of HF is expected to continue increasing over the coming decades. HFrEF constitutes a major public health concern, with five-year survival rates as low as 25%, and it carries with it a significant risk of emergency department visits and hospitalizations.
There has been increased focus recently on guideline-directed medical therapy (GDMT) in HFrEF, and evidence suggests that each ten percent improvement in measures of guideline-recommended composite care is associated with a thirteen percent lower odds of 24-month mortality. Nonetheless, research shows that substantial portions of patients are not treated with guideline-recommended doses, even after taking into account dose-limiting physiological parameters, and that guideline non-adherent practice is associated with poorer outcomes.
Target Audience:
The following HCPs: Cardiologists and PCPs; physician assistants, nurse practitioners, and pharmacists who practice in cardiology; and any other HCPs with an interest in or who clinically encounter patients with HFrEF.
See full details chevron_right- Cost: Free
- Credit hours: 1
- CME credits awarded by: ScientiaCME
- Material last updated: 05/06/2022
- Expiration of CME credit: 05/06/2024